GENMAB A/S GNMSF news, videos and press releases - Page 3
For more news please use our advanced search feature.
GENMAB A/S GNMSF - More news...
GENMAB A/S GNMSF - More news...
- Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
- Notice to Convene the Annual General Meeting of Genmab A/S
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Genmab announces initiation of share buy-back program
- Genmab Publishes 2020 Annual Report
- Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines
- Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
- CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
- Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
- Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
- Genmab to Present at the 39th Annual J.P. Morgan Healthcare Conference
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
- Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer
- Genmab Announces Enapotamab Vedotin Update
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab to Present at Jefferies Virtual London Healthcare Conference
- Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma